Farah, N;
Burt, R;
Ibrahim, AR;
Baker, R;
Kottaridis, PD;
(2020)
Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic.
British Journal of Haematology
, 190
(4)
E208-E210.
10.1111/bjh.16985.
Preview |
Text
Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leuk.pdf - Accepted Version Download (3MB) | Preview |
| Type: | Article |
|---|---|
| Title: | Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1111/bjh.16985 |
| Publisher version: | https://doi.org/10.1111/bjh.16985 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10112050 |
Archive Staff Only
 |
View Item |
